XT
RAPP

XTX Topco’s Rapport Therapeutics RAPP Stock Holding History

XTX Topco’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.56M Buy
61,441
+13,538
+28% +$498K 0.03% 874
2026
Q1 		$1.5M Buy
47,903
+34,841
+267% +$980K 0.03% 1084
2025
Q4 		$396K Buy
+13,062
New +$361K 0.01% 1818
2025
Q2 		– Sell
-15,442
Closed -$155K – 3327
2025
Q1 		$155K Buy
+15,442
New +$200K 0.01% 1760

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

XTX Topco's RAPP Position: Q2 2026 in Review

XTX Topco increased its Rapport Therapeutics (RAPP) stake by 28% in Q2 2026, buying an estimated $498K and bringing the position to 61,441 shares worth $2.56M. The position accounts for 0.03% of the portfolio, ranked #874.

XTX Topco first reported a position in RAPP in Q1 2025 and has held it in 4 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • XTX Topco held 61,441 shares of Rapport Therapeutics worth $2.56M as of Q2 2026.
  • XTX Topco bought 13,538 Rapport Therapeutics shares in Q2 2026, an estimated $498K.
  • Rapport Therapeutics made up 0.03% of XTX Topco's portfolio in Q2 2026, its #874 holding.
  • XTX Topco first reported a position in Rapport Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.